Study Name: To Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) 20 mg/0.5 ml New Formulation Administered Daily by Subcutaneous (SC) Inject
25 locations found
- Teva Investigational Site 10192
Location: Cullman, Alabama
- Teva Investigational Site 10204
Location: Fresno, California
- Teva Investigational Site 10201
Location: La Jolla, California
- Teva Investigational Site 10196
Location: Centennial, Colorado
- Teva Investigational Site 10184
Location: Miami, Florida
- Teva Investigational Site 10180
Location: Sarasota, Florida
- Teva Investigational Site 10197
Location: Sarasota, Florida
- Teva Investigational Site 10207
Location: Tampa, Florida
- Teva Investigational Site 10190
Location: Tampa, Florida
- Teva Investigational Site 10199
Location: Vero Beach, Florida
- Teva Investigational Site 10181
Location: Chicago, Illinois
- Teva Investigational Site 10202
Location: Northbrook, Illinois
- Teva Investigational Site 10188
Location: Patchogue, New York
- Teva Investigational Site 10198
Location: Charlotte, North Carolina
- Teva Investigational Site 10203
Location: Hickory, North Carolina
- Teva Investigational Site 10209
Location: Hickory, North Carolina
- Teva Investigational Site 10212
Location: Raleigh, North Carolina
- Teva Investigational Site 10215
Location: Winston Salem, North Carolina
- Teva Investigational Site 10213
Location: Winston-Salem, North Carolina
- Teva Investigational Site 10194
Location: Akron, Ohio
- Teva Investigational Site 10191
Location: Dayton, Ohio
- Teva Investigational Site 10200
Location: Uniontown, Ohio
- Teva Investigational Site 10214
Location: Cordova, Tennessee
- Teva Investigational Site 10206
Location: Cordova, Tennessee
- Teva Investigational Site 10186
Location: Nashville, Tennessee
|